(Q36830152)

16 August 2017

1 reference

title

Oral disease-modifying treatments for multiple sclerosis: the story so far. (English)

1 reference

16 August 2017

0 references

1

Bernd C Kieseier

1 reference

16 August 2017

2

Heinz Wiendl

1 reference

16 August 2017

publication date

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

21

1 reference

16 August 2017

issue

6

1 reference

16 August 2017

page(s)

483-502

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200721060-00005

16 August 2017

exact match

0 references

cites work

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721060-00005

Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. The MS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721060-00005

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721060-00005

Whole brain volume changes in patients with progressive MS treated with cladribine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721060-00005

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721060-00005

Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721060-00005

Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721060-00005

FTY720: mechanism of action and potential benefit in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721060-00005

FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721060-00005

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721060-00005

Cladribine: an investigational immunomodulatory agent for multiple sclerosis

21 January 2018

1 reference

12 December 2020

Suppression of experimental autoimmune neuritis by leflunomide

1 reference

12 December 2020

Current development of mTOR inhibitors as anticancer agents

1 reference

12 December 2020

Development of cladribine treatment in multiple sclerosis

1 reference

12 December 2020

Multiple sclerosis--the plaque and its pathogenesis

1 reference

12 December 2020

Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

1 reference

12 December 2020

Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data

1 reference

12 December 2020

The effect of cladribine on T(1) 'black hole' changes in progressive MS.

1 reference

12 December 2020

Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis.

1 reference

12 December 2020

The promise of minocycline in neurology.

1 reference

12 December 2020

Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis.

1 reference

12 December 2020

Metalloproteinases: mediators of pathology and regeneration in the CNS.

1 reference

12 December 2020

Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action

1 reference

12 December 2020

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

1 reference

12 December 2020

Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs

1 reference

12 December 2020

The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis

1 reference

12 December 2020

First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients

1 reference

12 December 2020

Cladribine in treatment of chronic progressive multiple sclerosis

1 reference

12 December 2020

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

12 December 2020

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Selective elimination of macrophages by dichlormethylene diphosphonate-containing liposomes suppresses experimental autoimmune neuritis

1 reference

12 December 2020

Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity

1 reference

12 December 2020

Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences

1 reference

12 December 2020

Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study

1 reference

12 December 2020

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

1 reference

12 December 2020

New directions in MS therapeutics: vehicles of hope

1 reference

12 December 2020

Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment

1 reference

12 December 2020

Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis

1 reference

12 December 2020

The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells.

1 reference

12 December 2020

Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system.

1 reference

12 December 2020

The many roles of chemokines and chemokine receptors in inflammation

1 reference

12 December 2020

Blockade of chemokine signaling in patients with multiple sclerosis

1 reference

12 December 2020

Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.

1 reference

12 December 2020

Mycophenolate mofetil and neurological diseases

1 reference

12 December 2020

Cladribine for multiple sclerosis: review and current status

1 reference

12 December 2020

Alpha lipoic acid inhibits human T-cell migration: implications for multiple sclerosis

1 reference

12 December 2020

HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis

1 reference

12 December 2020

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

12 December 2020

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

12 December 2020

Leflunomide Aventis Pharma

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

12 December 2020

Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin

1 reference

12 December 2020

Adherence to Medication

1 reference

12 December 2020

Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.

1 reference

12 December 2020

Treatment of multiple sclerosis with the pregnancy hormone estriol

1 reference

12 December 2020

The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system

1 reference

12 December 2020

1 reference

12 December 2020

Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials

1 reference

12 December 2020

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging

1 reference

12 December 2020

The role of B cells and autoantibodies in multiple sclerosis

1 reference

12 December 2020

The value of animal models for drug development in multiple sclerosis.

1 reference

12 December 2020

Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment

1 reference

12 December 2020

Matrix metalloproteinases in inflammatory demyelination: targets for treatment

1 reference

12 December 2020

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

1 reference

12 December 2020

Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors.

1 reference

12 December 2020

The treatment of chronic progressive multiple sclerosis with cladribine

1 reference

12 December 2020

Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon -1b

1 reference

12 December 2020

The role of integrins in immune-mediated diseases of the nervous system

1 reference

12 December 2020

Overview of azathioprine treatment in multiple sclerosis

1 reference

12 December 2020

Cladribine (2-chlorodeoxyadenosine)

1 reference

12 December 2020

Other therapy options and future strategies for treating patients with multiple sclerosis

1 reference

12 December 2020

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

1 reference

12 December 2020

Update on the medical treatment of juvenile idiopathic arthritis

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

12 December 2020

1 reference

12 December 2020

Update on the therapeutic potential of PDE4 inhibitors

1 reference

12 December 2020

FTY720 (fingolimod) in renal transplantation.

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Statins as a newly recognized type of immunomodulator

1 reference

12 December 2020

Emerging therapies in multiple sclerosis

1 reference

12 December 2020

Lipoic acid in multiple sclerosis: a pilot study

1 reference

12 December 2020

Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion

1 reference

12 December 2020

Mycophenolate mofetil in multiple sclerosis

1 reference

12 December 2020

The ups and downs of multiple sclerosis therapeutics

1 reference

12 December 2020

New treatments and azathioprine in multiple sclerosis

1 reference

12 December 2020

New concepts in the immunopathogenesis of multiple sclerosis

1 reference

12 December 2020

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

1 reference

12 December 2020

Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis

1 reference

12 December 2020

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

1 reference

12 December 2020

Inhibition of autoimmune encephalomyelitis by a tetracycline.

1 reference

12 December 2020

FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors

1 reference

12 December 2020

Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines

1 reference

12 December 2020

Mycophenolate-mofetil in the treatment of refractory multiple sclerosis.

1 reference

12 December 2020

Multiple sclerosis: a two-stage disease

1 reference

12 December 2020

Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.

1 reference

12 December 2020

Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.

1 reference

12 December 2020

An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS

1 reference

12 December 2020

A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis

1 reference

12 December 2020

Immunology of multiple sclerosis

1 reference

12 December 2020

Sirolimus: its discovery, biological properties, and mechanism of action

1 reference

12 December 2020

Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration

1 reference

12 December 2020

Effect of pioglitazone treatment in a patient with secondary multiple sclerosis

1 reference

12 December 2020

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

12 December 2020

Methotrexate for multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging

1 reference

12 December 2020

Current disease-modifying therapies in multiple sclerosis

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?

1 reference

12 December 2020

Statins--a cure-all for the brain?

1 reference

12 December 2020

Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship

1 reference

12 December 2020

Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis

1 reference

12 December 2020

Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation

1 reference

12 December 2020

New treatment approaches in metastatic renal cell carcinoma

1 reference

12 December 2020

Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies

1 reference

12 December 2020

Biochemical mechanisms of cyclosporine neurotoxicity

1 reference

12 December 2020

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.

1 reference

12 December 2020

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

1 reference

12 December 2020

Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis--results of the German multicenter study

1 reference

12 December 2020

Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats

1 reference

12 December 2020

Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice

1 reference

12 December 2020

The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy.

1 reference

12 December 2020

10.2165/00023210-200721060-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

16 August 2017

1038290313

0 references

1 reference